JWJeffrey Y. C. Wong

Jeffrey Y. C. Wong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jeffrey Y. C. Wong has a total of 206 co-authors. Here are the top co-authors by number of shared publications:

  • An Liu

    Departments of Radiation Oncology

    14 shared publications
  • Joseph Rosenthal

    Departments of Radiation Oncology, City of Hope, Duarte, CA, United States

    9 shared publications
  • George Somlo

    Departments of Radiation Oncology, City of Hope, Duarte, CA, United States

    7 shared publications
  • Anna M. Wu

    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California

    6 shared publications
  • Anthony Stein

    Departments of Radiation Oncology, City of Hope, Duarte, CA, United States

    6 shared publications
  • Stephen Forman

    Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California

    6 shared publications

Latest Publications

  • Open Access

    Carcinoembryonic Antigen (CEA) as a Therapeutic Target in Medullary Thyroid Cancer (MTC)

    by Kasey R. Bowyer, Marice B. Alcantara, Fang Fan, Colt A. Egelston, Paul J. Yazaki, Jeffrey Wong, Thinzar Lwin, Jack Shively, Maciej Kujawski, Krupal B. Patel

    Background/Objectives: Medullary thyroid cancer (MTC) is a rare but aggressive neuroendocrine malignancy arising from parafollicular C cells. Despite its low incidence, MTC has historically been estimated to account for 13.4% of thyroid cancer-related deaths. Survival outcomes remain limited in advanced disease, with a historical cohort reporting a 10-year survival of 21% for stage IV MTC, supporting the need for novel therapeutic approaches. Carcinoembryonic antigen (CEA), a fetal glycoprotein minimally expressed in normal adult tissues, is elevated in various malignancies and plays an established role in carcinogenesis, metastasis, and therapy resistance. In MTC, CEA is produced by neoplastic C cells alongside calcitonin, and both serum and tumor-associated CEA levels are markedly elevated relative to healthy tissue. More than half of MTC patients demonstrate elevated CEA, and intense CEA immunohistochemical staining correlates with aggressive, disseminated disease, highlighting its potential utility as both a biomarker and investigational therapeutic target in the disease. For MTC, surgery is the mainstay for locoregional disease with the intent for complete surgical resection when possible. Systemic therapy is generally reserved for structurally progressive, unresectable, symptomatic, or threatening advanced disease, with selective RET inhibitors used in RET-mutant disease and multi-kinase TKIs as additional treatment options. Although TKIs have improved progression-free survival, treatment can be limited by toxicities and the development of resistance over time. These limitations underscore the need for novel therapeutic strategies that can achieve more durable disease control and improve overall survival. Given its strong association with tumor burden, disease progression, and aggressive pathology, CEA represents a promising investigational target for therapeutic exploration in MTC. Methods: A narrative literature review was performed to evaluate carcinoembryonic antigen (CEA) as a therapeutic target and biomarker in medullary thyroid cancer (MTC). Searches were conducted in 2025 and 2026 using PubMed/MEDLINE, Embase, Cochrane Library, Scopus, Web of Science, and ClinicalTrials.gov. Conclusions: The current literature supports further investigation of CEA targeting as a therapeutic strategy in MTC. However, CEA is not yet a clinically validated therapeutic target and clinical trial data remain limited.

  • Open Access

    A Prospective First-In-Human Pilot Study 18F-DCFPyL Prostate-Specific Membrane Antigen Imaging on the RefleXion X1 Positron Emission Tomography-Computed Tomograpghy Subsystem in Patients with Prostate Cancer

    by Bo Liu, Savita Dandapani, Yun Li, Scott Glaser, Helen Chen, Tanya Dorff, Dave Yamauchi, Quan Chen, Kun Qing, Chengyu Shi, et al.


  • Open Access

    Evaluation of the Immunomodulatory Effects of Radiation for Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme

    by David Akhavan, Siddharth Subham, John D. Jeppson, Brenda Aguilar, Robyn A. Wong, Jonathan C. Hibbard, Susanta Hui, Jeffrey Y. C. Wong, Stephen J. Forman, Darya Alizadeh, et al.

    Standard-of-care treatment for Glioblastoma Multiforme (GBM) is comprised of surgery and adjuvant chemoradiation. Chimeric Antigen Receptor (CAR) T cell therapy has demonstrated disease-modifying activity in GBM and holds great promise. Radiation, a standard-of-care treatment for GBM, has well-known immunomodulatory properties and may overcome the immunosuppressive tumor microenvironment (TME); however, radiation dose optimization and integration with CAR T cell therapy is not well defined. Murine immunocompetent models of GBM were treated with titrated doses of stereotactic radiosurgery (SRS) of 5, 10, and 20 Gray (Gy), and the TME was analyzed using Nanostring. A conditioning dose of 10 Gy was determined based on tumor growth kinetics and gene expression changes in the TME. We demonstrate that a conditioning dose of 10 Gy activates innate and adaptive immune cells in the TME. Mice treated with 10 Gy in combination with mCAR T cells demonstrated enhanced antitumor activity and superior memory responses to rechallenge with IL13Rα2-positive tumors. Furthermore, 10 Gy plus mCAR T cells also protected against IL13Rα2-negative tumors through a mechanism that was, in part, c-GAS-STING pathway-dependent. Together, these findings support combination conditioning with low-dose 10 Gy radiation in combination with mCAR T cells as a therapeutic strategy for GBM.


  • Open Access

    Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches

    by Tanya Barauskas Dorff, Saro Kasparian, Natasha Garg, Sandy Liu, Sumanta Kumar Pal, Jeffrey Wong, Savita Dandapani

    Background: Metastasis-directed therapy is widely utilized for oligometastatic prostate cancer patients, but standard imaging does not always identify metastases definitively and, even with PSMA PET, there may be equivocal findings. Not all clinicians have access to detailed imaging review, particularly outside of academic cancer centers, and PET scan access is also limited. We sought to understand how imaging interpretation impacted recruitment to a clinical trial for oligometastatic prostate cancer. Methods: IRB approval was obtained to review medical records from all patients screened for the institutional IRB-approved clinical trial for men with oligometastatic prostate cancer involving androgen deprivation plus stereotactic radiation to all metastatic sites, as well as radium223 (NCT03361735). Clinical trial inclusion required at least one bone metastatic lesion and no more than five total sites of metastasis, including soft tissue sites. Tumor board discussion records were reviewed, along with results from additional radiology studies ordered or confirmatory biopsies performed. Clinical characteristics such as PSA level and Gleason score were studied for association with likelihood of oligometastatic disease confirmation. Results: At the time of data analysis, 18 subjects were deemed eligible and 20 were not eligible. The most common reasons for ineligibility were no confirmed bone metastasis in 16 patients (59%) and too many metastatic sites in 3 (11%). The median PSA of eligible subjects was 3.28 (range 0.4–45.5), whereas the median PSA of those found to be ineligible was 10.45 (range 3.7–26.3) when there were too many metastases identified, and 2.7 (range 0.2–34.5) when metastases were unconfirmed. PET imaging (PSMA or fluciclovine PET) increased the number of metastases, while MRI resulted in downstaging to non-metastatic disease. Conclusions: This research suggests that additional imaging (i.e., at least two independent imaging modalities of a possible metastatic lesion) or tumor board adjudication of imaging findings may be critical to correctly identify patients appropriate for enrollment in oligometastatic protocols. This should be considered as trials of metastasis-directed therapy for oligometastatic prostate cancer accrue and results are translated to broader oncology practice.


  • Autologous Stem Cell Transplantation With Intensity Modulated Total Body Irradiation Conditioning for Systemic Sclerosis

    by Colton Ladbury, Matthew Mei, Suzanne Kafaja, Jessica Nall, Chunhui Han, Savita Dandapani, Stephen Forman, Jeffrey Y.C. Wong


  • Open Access

    Volumetric modulated arc therapy based total marrow and lymphoid irradiation: Workflow and clinical experience

    by Colton Ladbury, Chunhui Han, An Liu, Jeffrey Y. C. Wong

    Background: The aim of this study is to report historical treatment planning experience at our institution for patients receiving total marrow and lymphatic irradiation (TMLI) using volumetric modulated arc therapy (VMAT) as part of the conditioning regimen prior to hematopoietic stem cell transplant.Methods: We identified a total of fifteen patients with VMAT TMLI, ten with a prescription dose of 20 Gy (targeting the skeletal bones, lymph nodes, spleen, and spinal canal, with 12 Gy to the brain and liver) and five with a prescription dose of 12-16 Gy (targeting the skeletal bones, lymph nodes, spleen, and spinal canal). Representative dosimetric parameters including total treatment time, mean and median dose, D80, and D10 (dose covering 80% and 10% of the structure volume, respectively) for targets and normal organs were extracted and compared to historical patients treated with helical tomotherapy.Results: The median treatment time for the first and subsequent fractions was 1.5 and 1.1 hours, respectively. All the target volumes had a mean dose greater than the prescribed dose except the ribs, which had an average mean dose of 19.5 Gy. The skeletal bones had an average mean dose of 21.1 Gy. The brain and liver have average mean doses of 14.8 and 14.1 Gy, respectively. The mean lung dose had an average of 7.6 ± 0.6 Gy for the 20-Gy cohort. Relative to the prescription dose of 20 Gy, the average mean dose for the normal organ volumes ranged from 16.5% to 72.0%, and the average median dose for the normal organs ranged from 16.5% to 71.0%. Dosimetry for patients treated to 12-16 Gy fell within expected ranges based on historical helical tomotherapy plans.Conclusions: Dosimetric data in the VMAT TMLI plans at our institution are summarized for 20 Gy and 12-16 Gy cohorts. Dose distributions and treatment times are overall similar to plans generated with helical tomotherapy. TMLI may be delivered effectively using a VMAT technique, even at escalated doses.


  • Open Access

    Oligometastatic Breast Cancer Patients Treated with High-Dose Chemotherapy and Targeted Radiation: Long-Term Follow-Up of a Phase II Trial

    by Colton Ladbury, Claire Hao, Christopher Ruel, Jason Liu, Scott Glaser, Arya Amini, Jeffrey Wong, Isaac Paz, Lucille Leong, Robert Morgan, et al.

    Background: Patients with oligometastatic breast cancer (oMBC) may benefit from aggressive local therapy. We sought to assess the effects of consolidative radiation therapy (RT) on outcomes in oMBC patients treated on a prospective phase II trial of high-dose chemotherapy (HDCT). Methods: Between 2005 and 2009, 12 patients with oMBC (≤3 metastatic sites) cancer were treated on protocol. Patients were to receive tandem HDCT supported by hematopoietic cell rescue (HCR). All radiographically identifiable oligometastatic sites received targeted radiation. Results: HDCT was initiated at a median of 6.7 (3.5–12.7) months after diagnosis of oMBC. Hormone receptors (HR) were positive in 91.6% of patients, and HER2 was overexpressed in 25% of patients. Median radiation dose (EQD2) was 41.2 (37.9–48.7) Gy. Median follow-up was 13.1 (6.8–15.1) years for living patients. Ten-year PFS and OS were 33% (95%CI, 10–59%) and 55% (95%CI, 22–79%), respectively. Durable local control of treated lesions was 87.5%. At the last follow up, two patients remained progression free and two more were without evidence of disease following additional salvage treatment. Conclusions: Although modern systemic therapies have obviated the use of HDC, aggressive local therapy warrants further evaluation and fractionated radiotherapy is a viable alternative if SBRT is not available.


  • Open Access

    Total marrow irradiation (TMI): Addressing an unmet need in hematopoietic cell transplantation - a single institution experience review

    by Jeffrey Y.C. Wong, An Liu, Chunhui Han, Savita Dandapani, Timothy Schultheiss, Joycelynne Palmer, Dongyun Yang, George Somlo, Amandeep Salhotra, Susanta Hui, et al.

    Purpose: TMI utilizes IMRT to deliver organ sparing targeted radiotherapy in patients undergoing hematopoietic cell transplantation (HCT). TMI addresses an unmet need, specifically patients with refractory or relapsed (R/R) hematologic malignancies who have poor outcomes with standard HCT regimens and where attempts to improve outcomes by adding or dose escalating TBI are not possible due to increased toxicities. Over 500 patients have received TMI at this center. This review summarizes this experience including planning and delivery, clinical results, and future directions.Methods: Patients were treated on prospective allogeneic HCT trials using helical tomographic or VMAT IMRT delivery. Target structures included the bone/marrow only (TMI), or the addition of lymph nodes, and spleen (total marrow and lymphoid irradiation, TMLI). Total dose ranged from 12 to 20 Gy at 1.5-2.0 Gy fractions twice daily.Results: Trials demonstrate engraftment in all patients and a low incidence of radiation related toxicities and extramedullary relapses. In R/R acute leukemia TMLI 20 Gy, etoposide, and cyclophosphamide (Cy) results in a 1-year non-relapse mortality (NRM) rate of 6% and 2-year overall survival (OS) of 48%; TMLI 12 Gy added to fludarabine (flu) and melphalan (mel) in older patients (≥ 60 years old) results in a NRM rate of 33% comparable to flu/mel alone, and 5-year OS of 42%; and TMLI 20 Gy/flu/Cy and post-transplant Cy (PTCy) in haplo-identical HCT results in a 2-year NRM rate of 13% and 1-year OS of 83%. In AML in complete remission, TMLI 20 Gy and PTCy results in 2-year NRM, OS, and GVHD free/relapse-free survival (GRFS) rates of 0%, 86·7%, and 59.3%, respectively.Conclusion: TMI/TMLI shows significant promise, low NRM rates, the ability to offer myeloablative radiation containing regimens to older patients, the ability to dose escalate, and response and survival rates that compare favorably to published results. Collaboration between radiation oncology and hematology is key to successful implementation. TMI/TMLI represents a paradigm shift from TBI towards novel strategies to integrate a safer and more effective target-specific radiation therapy into HCT conditioning beyond what is possible with TBI and will help expand and redefine the role of radiotherapy in HCT.


  • Open Access

    Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early Follow-Up

    by Colton Ladbury, Saro Armenian, Alysia Bosworth, Tianhui He, F. Lennie Wong, Savita Dandapani, Chunhui Han, An Liu, Monzr Al Malki, Joseph Rosenthal, et al.